FDA’s Office of Generic Drugs appears to be in the midst of a lull in application submissions following an unprecedented single-month surge in volume, likely because many sponsors want the benefit of a formal review goal.
The respite should allow reviewers some valuable time to catch up with filing and review tasks, as well as to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?